Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
Department of Anesthesiology
1980
Lebowitz PW, Savarese JJ.  1980.  Complications involving neuromuscular pharmacology.. Int Anesthesiol Clin. 18(3):139-56.
Yao FS, Seidman SF, Artusio JF.  1980.  Disturbance of consciousness and hypocalcemia after neomycin irrigation, and reversal by calcium and physostigmine.. Anesthesiology. 53(1):69-71.
Donlon JV, Savarese JJ, Ali HH, Teplik RS.  1980.  Human dose-response curves for neuromuscular blocking drugs: a comparison of two methods of construction and analysis.. Anesthesiology. 53(2):161-6.
Martyn JA, Szyfelbein SK, Ali HH, Matteo RS, Savarese JJ.  1980.  Increased d-tubocurarine requirement following major thermal injury.. Anesthesiology. 52(4):352-5.
Lebowitz PW, Ramsey FM, Savarese JJ, Ali HH.  1980.  Potentiation of neuromuscular blockade in man produced by combinations of pancuronium and metocurine or pancuronium and d-tubocurarine.. Anesth Analg. 59(8):604-9.
Ali HH, Savarese JJ.  1980.  Stimulus frequency and dose-respone curve to d-tubocurarine in man.. Anesthesiology. 52(1):36-9.
1981
Lebowitz PW, Ramsey FM, Savarese JJ, Ali HH, deBros FM.  1981.  Combination of pancuronium and metocurine: neuromuscular and hemodynamic advantages over pancuronium alone.. Anesth Analg. 60(1):12-7.
Friedberg SJ, Gomillion M.  1981.  Hydrogen exchange in the formation of dihydroxyacetone phosphate from acyl dihydroxyacetone phosphate in O-alkyl lipid synthesis in Ehrlich ascites tumor cell microsomes.. J Biol Chem. 256(1):291-5.
Savarese JJ.  1981.  The new neuromuscular blocking drugs are here.. Anesthesiology. 55(1):1-3.
Moss J, Rosow CE, Savarese JJ, Philbin DM, Kniffen KJ.  1981.  Role of histamine in the hypotensive action of d-tubocurarine in humans.. Anesthesiology. 55(1):19-25.
Ali HH, Savarese JJ, Lebowitz PW, Ramsey FM.  1981.  Twitch, tetanus and train-of-four as indices of recovery from nondepolarizing neuromuscular blockade.. Anesthesiology. 54(4):294-7.
Philbin DM, Moss J, Akins CW, Rosow CE, Kono K, Schneider RC, VerLee TR, Savarese JJ.  1981.  The use of H1 and H2 histamine antagonists with morphine anesthesia: a double-blind study.. Anesthesiology. 55(3):292-6.
1982
Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE.  1982.  Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant.. Anesth Analg. 61(9):723-9.
Moss J, Philbin DM, Rosow CE, Basta SJ, Gelb C, Savarese JJ.  1982.  Histamine release by neuromuscular blocking agents in man.. Klin Wochenschr. 60(17):891-5.
Rosow CE, Moss J, Philbin DM, Savarese JJ.  1982.  Histamine release during morphine and fentanyl anesthesia.. Anesthesiology. 56(2):93-6.
Martyn JA, Matteo RS, Greenblatt DJ, Lebowitz PW, Savarese JJ.  1982.  Pharmacokinetics of d-tubocurarine in patients with thermal injury.. Anesth Analg. 61(3):241-6.
Ryan TA.  1982.  Psychology at Cornell after Titchener: Madison Bentley to Robert Macleod, 1928-1948.. J Hist Behav Sci. 18(4):347-69.
1983
Savarese JJ, Ali HH, Basta SJ, Sunder N, Moss J, Gionfriddo MA, Lineberry CG, Wastila WB, el-Sayad HA, Montague D et al..  1983.  The clinical pharmacology of BW A444U. A nondepolarizing ester relaxant of intermediate duration.. Anesthesiology. 58(4):333-41.
Ali HH, Savarese JJ, Basta SJ, Sunder N, Gionfriddo M.  1983.  Evaluation of cumulative properties of three new nondepolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium.. Br J Anaesth. 55 Suppl 1:107S-111S.
Basta SJ, Savarese JJ, Ali HH, Moss J, Gionfriddo M.  1983.  Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine.. Br J Anaesth. 55 Suppl 1:105S-106S.
1984
Hemmings HC, Williams KR, Konigsberg WH, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. I. Amino acid sequence around the phosphorylated threonine.. J Biol Chem. 259(23):14486-90.
Hemmings HC, Nairn AC, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1.. J Biol Chem. 259(23):14491-7.
Ouimet CC, Miller PE, Hemmings HC, Walaas SI, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization.. J Neurosci. 4(1):111-24.
Hemmings HC, Nairn AC, Aswad DW, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus.. J Neurosci. 4(1):99-110.
Hemmings HC, Greengard P, Tung HY, Cohen P.  1984.  DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.. Nature. 310(5977):503-5.